HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's financial performance shows a decline in revenue, which is negative, but they have strong cash reserves. The strategic plan highlights potential growth through FDA approvals and partnerships, which is positive. The Q&A reveals some uncertainties in regulatory paths and timelines, which could cause concern. Overall, the mixed signals from financials, strategic growth plans, and uncertainties result in a neutral sentiment.
Key Financial Performance
Net Loss for Full Year 2025 $21 million or $0.62 per basic and diluted share, reflecting strong financial discipline. A meaningful portion of this net loss relates to noncash expenses, primarily stock-based compensation.
Net Loss for Fourth Quarter 2025 $5.3 million or $0.15 per share, directly in line with expectations. This represents a 30% decrease compared to the same quarter last year, attributed to maintaining a lean organization and carefully pacing investments.
Net Cash Used in Operating Activities for Full Year 2025 Less than $14 million, representing a 3% decrease year-over-year, showcasing financial discipline and efficient operations.
Net Cash Used in Operating Activities for Fourth Quarter 2025 $2.9 million, representing a 30% decrease compared to the same quarter last year, attributed to a lean organization and careful investment pacing.
Cash and Cash Equivalents and Restricted Cash $4.4 million as of December 31, 2025, demonstrating access to capital markets and support from long-term stakeholders.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
HeartBeam System: Developed the first-ever portable cable-free ECG that can synthesize a 12-lead ECG. Achieved FDA 510(k) clearance for arrhythmia assessment in December 2025.
12-lead Patch: Unveiled a working prototype of an on-demand 12-lead patch, targeting the $2 billion ambulatory cardiac monitoring market. The patch integrates existing reimbursement workflows and offers better diagnostic capabilities.
Concierge and Preventive Cardiology Practices: Initial commercial launch targeting high-net-worth individuals and concierge practices in key markets like New York, South Florida, Dallas, and Southern California. Target price per patient is $500-$1,000 per year.
Expansion Opportunities: Future plans to expand into direct primary care practices, telehealth networks, and national healthcare organizations.
Commercial Launch Strategy: Focused rollout with partnerships like ClearCardio. Business model designed for scalability with a subscription model and margins above 70%.
AI Collaboration: Strategic collaboration with Mount Sinai to develop advanced AI algorithms for disease prediction and management.
Heart Attack Detection: Initiated ALIGN-ACS pilot study in Europe to compare HeartBeam ECG to standard 12-lead ECG for heart attack detection. Study expected to complete by Q3 2026.
AI Development: Developing personalized AI algorithms to enhance diagnostic capabilities and expand market opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: HeartBeam received a 'not substantially equivalent' (NSE) letter from the FDA in November, which could have delayed product clearance. Although the issue was resolved quickly, it highlights potential regulatory hurdles.
Market Adoption Risks: The company is targeting a niche market of concierge and preventive cardiology practices, which may limit initial adoption. The success of the commercial launch depends on proving willingness to pay and achieving deep adoption within these practices.
Financial Sustainability: HeartBeam reported a net loss of $21 million for 2025 and has limited cash reserves of $4.4 million as of December 31, 2025. The company is reliant on external funding to sustain operations and execute its strategic initiatives.
Competitive Pressures: The ambulatory cardiac monitoring market is a $2 billion revenue market with established players. HeartBeam's new 12-lead patch faces competition from existing long-term continuous monitors and mobile cardiac telemetry devices.
Operational Risks: The company is in the early stages of commercializing its technology and scaling operations. Any delays in product rollout or failure to meet milestones could impact financial performance and market credibility.
Technological Risks: HeartBeam's success depends on the performance and reliability of its innovative 12-lead ECG technology and AI algorithms. Any technical issues or failure to meet clinical expectations could hinder adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: HeartBeam expects to achieve breakeven with approximately 30,000 patients enrolled in its subscription model. The company anticipates scaling revenue significantly in 2027 after demonstrating deep adoption with anchor accounts in 2026.
Market Trends and Expansion: The company is focusing its initial commercial launch on concierge and preventive cardiology practices, targeting high-net-worth individuals and concierge physicians. Expansion opportunities include direct primary care practices, telehealth networks, and national healthcare organizations. The 12-lead patch is expected to disrupt the $2 billion ambulatory cardiac monitoring market, with potential to shift 50% of the market and grow it by 30%.
Product Development and Launch: HeartBeam is launching its 12-lead synthesis software and credit card-sized ECG device in 2026, targeting concierge cardiology practices. The company is also developing a 12-lead patch, which is currently in clinical trials and expected to disrupt the cardiac monitoring market. The ALIGN-ACS pilot study for heart attack detection is expected to complete by Q3 2026, informing the design of an FDA pivotal study.
AI and Technology Advancements: HeartBeam is collaborating with Mount Sinai to develop AI algorithms for heart attack detection and disease prediction. These algorithms aim to enhance the diagnostic capabilities of the HeartBeam system and expand its applications to wellness and clinical assessments.
Financial Projections: Baseline operating cash outflows for 2026 are expected to remain at $14 million, with additional investments of $3-5 million for R&D and commercialization efforts. Gross operating cash outflows are projected to be $17-19 million for 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk a little bit more about the timelines for the ALIGN pilot study and patch initiatives?
A:Robert Eno explained that the ALIGN-ACS pilot study involves about 100 patients and is expected to enroll quickly, with completion anticipated by the end of Q3. The study will inform a pivotal study required for FDA approval. Discussions with the FDA are ongoing, and the regulatory path and timelines will be shared as they progress. Regarding the patch, it is expected to follow a 510(k) regulatory path, and the go-to-market strategy is still being determined, with potential partnerships being explored to expedite patient access.
Q:What does the account pipeline look like, and how many anchor accounts would you expect to have up and running over the next 6 months?
A:Bryan Humbarger stated that they are focusing on a premium patient population of about 150,000 patients concentrated in 3-4 U.S. geographies. They aim to validate their premium value proposition with several accounts in the first couple of quarters and then scale. Initial accounts have 400-4,000 patients, and the focus is on deep adoption and proving efficiency before expanding to larger chains.
Q:How should we think about R&D spending trends and cadence for the year?
A:Timothy Cruickshank noted that R&D spending will step up slightly in the first half of the year due to clinical trial enrollment and patch development but will return to current levels in the second half. The overall cash outflow for the year is projected at $17-19 million, with about $1.5 million incremental for R&D initiatives.
Q:Will the focus on the top 10% of concierge practices continue well into 2027?
A:Bryan Humbarger indicated that they plan to validate the model quickly and expand into the broader 1.5 million patient market before 2027. The focus on the top 10% is due to the high alignment with their product and the efficiency of contracting with physician-owned practices.
Q:Does the pricing include the reader service, and is there a plan for reimbursement codes?
A:The pricing of $500-$1,000 includes the reader service. Robert Eno mentioned that while reimbursement codes are part of the long-term strategy, the current focus is on patient pay opportunities, particularly in the concierge market. They believe they can achieve cash flow positive without immediate reimbursement.
Q:What kind of accuracy is needed for the ALIGN-ACS study to move forward with the pivotal study?
A:Robert Eno stated that the goal is to show accuracy comparable to a 12-lead ECG. The study design uses emergency room data as an analog for home use, focusing on reducing delays in patient action. The device is positioned as a rule-in tool to speed up decision-making.
Q:Is there interest in profit-sharing models or targeting telehealth providers?
A:Bryan Humbarger mentioned that they are open to exploring profit-sharing models as they scale but are currently focused on a subscription model. They see opportunities with telehealth providers, emphasizing the unique value of their clinical-grade 12-lead ECG for differentiation.
Q:What is the background of the Mount Sinai partnership, and are similar alliances being considered?
A:Robert Eno explained that the Mount Sinai partnership evolved from existing relationships and mutual respect. Mount Sinai values HeartBeam's ability to bring 12-lead ECG algorithms to patients at home. They are open to similar partnerships with like-minded organizations.
Q:What is the regulatory path for new indications, and will a sales team be needed to market the device?
A:The patch is expected to follow a 510(k) path, while the regulatory path for heart attack detection is still being determined. Bryan Humbarger stated that a lean sales team will initially focus on strategic accounts, with potential expansion to 3-5 additional team members by 2026.
Q:What is the excitement level among cardiologists about the HeartBeam system?
A:Bryan Humbarger reported high excitement among cardiologists, who appreciate the clinical-grade 12-lead ECG quality and its potential to transform patient care. The system's ability to provide a complete heart picture in a portable format is seen as a game-changer.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the regulatory path and timelines for the heart attack detection device, stating that discussions with the FDA are ongoing. They also did not clarify the exact profit-sharing arrangements or the timeline for expanding beyond the top 10% of concierge practices.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI algorithm
ALIGN ACS
CEO Chief
Chief Commercial
Chief Officer
Commercial Officer
Dallas
ECG heart
ECG lead
ECG potential
HeartBeam ECG
Holter monitor
Humbarger Chief
MCT
Mount Sinai
Officer Director
Sinai expertise
attack detection
capital
core technology
demand lead
detection lead
form factor
lead ECG
lead patch
loss
monitoring
patch AI
platform
prototype
reimbursement
segment
technology form
week
willingness
BEAT Transcript
HeartBeam, Inc. (BEAT) Q4 2025 Earnings Call Transcript
Unknown3-12
The company's financial performance shows a decline in revenue, which is negative, but they have strong cash reserves. The strategic plan highlights potential growth through FDA approvals and partnerships, which is positive. The Q&A reveals some uncertainties in regulatory paths and timelines, which could cause concern. Overall, the mixed signals from financials, strategic growth plans, and uncertainties result in a neutral sentiment.
HeartBeam, Inc. (BEAT) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals a mixed sentiment. While there are positive developments like productive FDA discussions and strategic partnerships, concerns arise due to limited cash reserves and lack of detailed guidance on pricing and funding. The Q&A reflects cautious optimism but lacks clarity on key issues. The strategic focus on capital efficiency and market expansion is positive, yet the absence of immediate revenue growth and the need for further funding temper expectations. Given these factors, a neutral stock price movement is anticipated over the next two weeks.
HeartBeam, Inc. (BEAT) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presented a mixed picture: positive aspects include a decrease in operating cash use and progress towards FDA clearance, but concerns arise from the need for additional funding and lack of detailed guidance on strategic partnerships and pricing. The Q&A section did not reveal major risks but highlighted uncertainties around commercialization timelines and partnerships. The neutral sentiment stems from balancing these positive and negative elements, with no strong catalyst for significant stock movement.
HeartBeam, Inc. (BEAT) Q1 2025 Earnings Call Transcript
Unknown5-13
The earnings call highlights potential opportunities in the market and strategic partnerships, but also reveals significant risks such as dependence on FDA clearance and financial challenges. The public offering suggests a need for cash, while the Q&A section indicates some uncertainty in management's responses. The neutral sentiment is due to mixed signals: potential growth and partnerships are offset by regulatory and financial risks, along with unclear guidance on key timelines.
BEAT Slides
BEAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
